FDA grants Breakthrough Therapy designation to AP-SA02
Armata Pharmaceuticals received a Breakthrough Therapy designation from the FDA for AP-SA02 based on Phase 2 clinical data showing potential for substantial improvement over existi…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Armata Pharmaceuticals received a Breakthrough Therapy designation from the FDA for AP-SA02 based on Phase 2 clinical data showing potential for substantial improvement over existi…
Perspective Therapeutics and Merck are partnering to evaluate [212Pb]PSV359 combined with Keytruda in solid tumors, potentially reshaping the tumor microenvironment for improved ca…
Lipocine began its BLOOM Phase 3 trial for LPCN 1154 to support a potential 505(b)(2) NDA, utilizing existing resources despite past data anomalies.
WhiteFiber, Inc. filed an 8-K with an investor presentation, explicitly noting it contains forward-looking statements and cautioning about the risks and uncertainties involved. The…
The company received notification from Nasdaq that its Class A ordinary shares closed below $1.00 per share for 30 consecutive business days, triggering a 180-day monitoring period…
The accounting firm consented to the incorporation of its previous audits into the current Form 8-K filing regarding People Inc. Subsidiaries, ensuring regulatory compliance for re…
Caring Brands filed an unaudited pro forma balance sheet showing $8.22 million in stockholders' equity following capital market transactions, designed to meet Nasdaq's minimum $2.5…
Regulators are soliciting comments on proposed third-party risk management guidance and issuing a statement regarding community bank core service provider engagement.
New Fortress Energy Inc. filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, effective on the filing date, to amend and restate the com…
AtaiBeckley filed an amended certificate of incorporation with the SEC, detailing its corporate structure and authorized shares. The restructuring affects compliance documentation …
Aon's auditors consented to incorporating their report for certain S-3 and S-8 filings, ensuring regulatory compliance on past financial statements.
Opus Genetics announced 3-month results from the low dose cohort of its OPGx-BEST1 study, a gene therapy for BEST1-related retinal disease. The ongoing trial may impact clinical de…
Agencies reduce regulations for community banks and expand eligibility for the 18-month exam cycle.
Z Squared Inc. filed an amendment to its Third Amended and Restated Bylaws to update corporate governance procedures. Market impact is likely neutral.
GeoVax requested a hearing before the Nasdaq Hearings Panel to appeal a bid price delisting trigger, with the hearing scheduled for October 13, 2026, following a request to stay su…
KIDZ AI has amended its certificate of incorporation to increase the number of authorized common shares, a common corporate action necessary to facilitate future fundraising or ope…
Vicor Corporation filed an exhibit with the SEC updating its Articles and Bylaws, modifying which proposals may be considered at the Annual Meeting.
Fortune CPA, Inc provided a consent for the East West Ave Acquisition Corp. filing, accepting liability only for statements regarding its own company.
CervoMed announced initial 12-week biomarker results from its Phase 2a trial of neflamapimod for nfvPPA will be presented as a late-breaking oral session at the ISFTD conference in…
Stark Focus Group filed a certificate of amendment, as required to effect a reverse stock split. The move aims to comply with Nasdaq listing requirements for continued listing.